1. Introduction {#s0005}
===============

Mitochondrial DNA (mtDNA) is replicated by the DNA polymerase γ, or Pol γ, which in animals is the only DNA polymerase present in mitochondria. The catalytic subunit of Pol γ belongs to a subfamily of the prokaryotic PolA family and its amino acid sequence is well conserved from yeast to humans. Structurally, human Pol γ is a heterotrimer composed of one catalytic subunit, which is encoded by POLG(1), and two accessory subunits, which are encoded by POLG2 ([@bb0310]). The catalytic subunit contains an N-terminal exonuclease domain (residues 170--440), a C-terminal polymerase domain (residues 440--475 and 785--1239) and a spacer region encompassing residues 475--785 ([@bb0160]). To date, about 250 pathological mutations associated with severe mitochondrial disorders have been identified in POLG (<http://tools.niehs.nih.gov/Polg/>). Among them, a few mutations have been recently described to be involved in stavudine-induced toxicity ([@bb0070; @bb0315]), in valproate-induced hepatotoxicity ([@bb0220; @bb0255]), in testicular cancer ([@bb0050]), in breast tumorigenesis ([@bb0010; @bb0210; @bb0230]) and in idiopathic sporadic parkinsonism ([@bb0185; @bb0115]). Besides these pathological mutations, several single nucleotide polymorphisms (SNPs) have been identified in Pol γ, most of which appear to be, or are considered, neutral polymorphisms. Traditionally, a SNP is defined as a DNA sequence variation occurring within a population with an allelic frequency higher than 1%. Using next generation sequencing techniques applied to the exome, and to full genome sequencing, such as the 1000 Genomes Project (<http://www.1000genomes.org/>), a great number of new polymorphisms have been identified with a frequency much lower than 1%, so that now any nucleotide variation is generally considered as a SNP. A polymorphism differs from a pathological mutation since it is not associated with any pathology. However, several SNPs/polymorphisms behave as phenotypic modifiers of other mutations, or may alter the response to certain drugs or the susceptibility to environmental factors such as toxins, making them the subject of pharmacogenetic and toxicogenetic research.

In Pol γ, more than 1000 polymorphisms have been identified, most of which are non-coding or synonymous. Coding and non-synonymous SNPs have not yet been characterized so it is not known if they really are neutral polymorphisms. An exception is the E1143G mutation, which appears with a frequency of 3--4% in the European population (GeneSNps) and its effects on human Pol γ have been the subject of several studies. However, *in vitro* studies led to contradictory conclusions on the role of this mutation as a modulator of mutations or neutral polymorphism ([@bb0060; @bb0200]).

The *Saccharomyces cerevisiae* DNA polymerase γ, encoded by the *MIP1* gene, shows 43% similarity with the human Pol γ catalytic subunit. Thanks to this similarity, yeast has been largely used to validate the role of human putative pathological mutations, to understand biochemical consequences associated with these mutations, to find molecules able to rescue their detrimental effects and to study the pharmacogenetics of drugs such as valproate and stavudine ([@bb0075; @bb0035; @bb0040; @bb0020; @bb0025; @bb0215; @bb0250; @bb0255; @bb0260; @bb0265; @bb0275; @bb0270; @bb0280]). Yeast is a suitable model organism for the study of the effects of Pol γ mutations on mtDNA stability, thanks to its ability to survive in the absence of a functional mitochondrial genome. Yeast cells containing deletions-carrying mtDNA, called *rho^−^*, or cells which have completely lost mtDNA, called *rho^0^*, are respiratory-deficient and produce small-sized colonies, called *petite*. *Petite* mutants arise spontaneously with high frequency (approximately 10^− 2^) ([@bb0085]), which is increased in the case of Mip1 mutant strains with reduced polymerase activity. *Petite* mutability can be easily measured and provides an estimate of the mtDNA extended mutability, *i.e.* loss or rearrangements in mtDNA. mtDNA point mutability can also be easily measured as the frequency of spontaneous mutants which are resistant to erythromycin (Ery^R^ mutants), an antibiotic that inhibits mitochondrial but not cytoplasmic translation. In fact, resistance to erythromycin is acquired through specific transversions or transitions in the mitochondrial gene encoding the 21 S rRNA ([@bb0080; @bb0240; @bb0245; @bb0295]). Ery^R^ mutability is increased by Mip1 mutations which reduce the fidelity of replication.

Yeast has also been used to evaluate the correlation between specific mutations in Mip1, corresponding to human mutations, and mtDNA mutability induced by treatment with stavudine (3′-deoxy-2′,3′-didehydrothymidine, or d4T) ([@bb0035]), a nucleoside reverse transcriptase inhibitor (NRTI) which has been successfully used in the highly active antiretroviral therapy (HAART). Although HAART has significantly increased the life expectancy of HIV patients, prolonged treatment can induce side effects in some patients, most of which are due to the interference of the NRTIs with mitochondrial metabolism. Several observations suggest that NRTIs mitochondrial toxicity depends on their interference with Pol γ activity ([@bb0145; @bb0150; @bb0155; @bb0170]), at least in part and especially for pyrimidine analogs such as stavudine and zalcitabine (2′,3′-dideoxycytidine, or ddC). It has been also demonstrated that several triphosphorylated NRTIs can inhibit the activity of human Pol γ *in vitro* ([@bb0135; @bb0175; @bb0190]). According to the "Pol γ hypothesis", NRTI toxicity could be due to direct inhibition of polymerase catalytic activity, incorporation of NRTI in the nascent strand with subsequent chain termination or persistence of the analog in mitochondrial DNA because of inefficient excision ([@bb0165]). Consequently, some mutations in Pol γ can result in different biochemical properties towards the NRTI-triphosphate (NRTI-TP), such as a greater K~i~ by the NRTI-TP, a lower NRTI-TP discrimination or a lower excision efficiency of the NRTI from the mtDNA and can increase the susceptibility to NRTIs toxicity, as was shown for patients carrying the mutation R964C ([@bb0015; @bb0315]). Thus, a pharmacogenetic approach in the NRTI treatment requires to establish whether polymorphisms are neutral or if they affect mtDNA polymerase activity.

The aim of this study is to characterize, by the use of specific *ad hoc* yeast models, some polymorphisms in Pol γ, in order to assess whether they are neutral nucleotide variations or not. Specifically, we will try to answer the following questions: (i) Is the mutation neutral, *i.e.* does the mutant Mip1 behave *in vivo* like the wt Mip1 concerning mtDNA extended and point mutability? (ii) Is the mutation a phenotypic modifier or mutation modulator, *i.e.* can the mutation worsen the phenotype of an *in cis* pathological mutation? (iii) Does the mutation increase the toxicity induced by stavudine or zalcitabine treatment? An answer to the last question is of particular relevance in view of possible pharmacogenetic applications.

We found that most of the considered polymorphisms are not neutral but rather behave as phenotypic modifiers, and that three polymorphisms, besides the R964C and E1143G mutations previously studied ([@bb0035]), showed an altered sensitivity to stavudine and/or zalcitabine toxicity.

2. Materials and methods {#s0010}
========================

2.1. Strains, plasmids and media {#s0015}
--------------------------------

The yeast strains used in this work are reported in [Table 1](#t0005){ref-type="table"}. The primers used are reported in Supplementary Table 1. Yeast media are YP (1% yeast extract (Formedium), 2% peptone (Formedium)) or SC (0.69% yeast nitrogen base without amino acids (Formedium), 0.1% drop out mix according to [@bb0140]). Appropriate carbon sources were added to the medium at a final concentration of 2%. 5-FOA plates contained 0.69% yeast nitrogen base without amino acids, 1% fluoroorotic acid (Formedium), 40 mg/l of each amino acid or base necessary to complement the auxotrophy, 40 mg/l uracil and 2% glucose. YPGen and YPHyg were YP supplemented with 200 mg/l G418 sulfate (Gibco) or 250 mg/l hygromycin B (Formedium). YPAEG-Ery medium contained 1% yeast extract (Difco), 2% peptone (Difco), 100 mg/l adenine, 3% \[v/v\] glycerol, 3% \[v/v\] ethanol, 3 g/l erythromycin (Sigma). If necessary, the medium was solidified by adding 2% agar (Formedium).

Human *ENT1* was disrupted by using the one step gene disruption technique, with the *HIS5* gene from *Schizosaccharomyces pombe* cassette. The *SpHIS5* cassette, flanked by 40--45 bp of *hENT1*, was amplified by using pUG27 ([@bb0120]) as a template and oligonucleotides hENT1DFw and hENT1D2Rv as primers. The cassette was introduced in strain YLV3t3m3 and the disruption was confirmed by PCR, thus obtaining the YLV3t3m3∆H strain.

For construction of the strain W1BCK1, a fragment of pFL61 containing the PGK promoter and the PGK terminator was digested with *Bam*HI and *Bgl*II from plasmid pFL61, and subcloned in *Bam*HI-digested pFL26 integrative plasmid ([@bb0055; @bb0195]). Human *DCK1* cDNA was amplified with primers DCKcFw and DCKcRv, digested with *Not*I and subcloned in pFL26PGK under the control of the PGK promoter. The plasmid was introduced into the strain W303-1B and transformants in which the plasmid was integrated at the *leu2* locus were selected on SC medium without leucine. Integration was verified by PCR.

For construction of the strain W1BCK1-10B, the *mip1*::*HphMX4* cassette was amplified from DWM-9A genomic DNA ([@bb0045]) with primers MIP1DFw and MIP1Drv, and introduced into the W1BCK strain. Disruption was verified by phenotypic analysis and PCR.

Human *CNT3* cDNA was amplified with primers hCNT3Fw and hCNT3Rv, and cloned in the centromeric plasmid pUSG-E12 (a personal gift of A. Inga) after digestion with *Xho*I and *Not*I, and in the episomal plasmid pYES2 (Life Technologies) after digestion with *Hind*III and *Not*I. In both plasmids, the *hCNT3* ORF was cloned under the *GAL1-10* promoter.

2.2. Construction of mutant *mip1* strains {#s0020}
------------------------------------------

*mip1* mutant alleles were constructed through mutagenic overlap PCR ([@bb0125]). After overlap PCR, the *MIP1* fragments containing mutations E166Q, E166R, P207L or L340V were digested with *Not*I and *Avr*II and subcloned in pFL39*MIP1* ([@bb0040]), whereas *MIP1* fragments containing mutations Y753F, S889R, S899W, K903R or K903C were digested with *Avr*II and *Bsr*GI and subcloned in the same plasmid. *mip1* mutant alleles harboring G224A, A692T, E698G, Q766R, Q766C and E900G were constructed previously ([@bb0040; @bb0020; @bb0250; @bb0260]). *mip1* double mutant alleles were constructed by overlap PCR using *mip1^A692T^* as template instead of *MIP1* wt allele.

Strains DWM-5A/pFL38*MIP1*, YLV3t3m3/pFL38*MIP1* and W1BCK1-10/pFL38*MIP1* were transformed by the LiAc/ssDNA/PEG method ([@bb0100; @bb0105]) with pFL39 plasmid harboring *mip1* wt and mutant alleles, thus obtaining heteroallelic strains. Subsequently, pFL38*MIP1* was counter-selected in the presence of 5-fluoroorotic acid as previously reported ([@bb0025]), thus obtaining *mip1* mutant haploid strains.

2.3. Northern blot, RT-PCR and RT-qPCR {#s0025}
--------------------------------------

For Northern blot on strain YLV3t3m3, total RNA was prepared from cells grown to OD~600~ = 1 in YP medium supplemented with 2% glucose, which inhibits expression by *GAL* promoter, 0.3% galactose or 2% galactose, which induces expression by *GAL* promoter, with or without d4T, by extraction with hot acidic phenol ([@bb0005]). Northern analysis was carried out as previously reported ([@bb0225]). *ENT1*, *HSV-TK* and *ACT1* probes were obtained by PCR-amplification using primers hENT1Fw and hENT1Rv, TK1Fw and TK1Rv, ACT1Fw and ACT1Rv, respectively. The probes were labeled with Easytides \[α-32P\]dCTP 3000 Ci/mmol (PerkinElmer) by the rediprime DNA-labeling system (Amersham). Signals were quantified using Multi-Analyst software (Bio-Rad).

For the reverse transcription, total RNA prepared from YLV3t3m3 or YLV3t3m3ΔH was treated with DNase I (New England Biolabs), retro-transcribed with M-MuLV Reverse Transcriptase (New England Biolabs) with oligo (dT)~20~primer (Euroclone) and murine RNase inhibitor (New England Biolabs). PCR on retro-transcribed *hCNT3* and, as reference, *ACT1*, was performed using hCNT3cFw and hCNT3cRv or ACT1Fw and ACT1Rv primers. qPCR on retro-transcribed *hDCK1*, *MIP1* and, as reference, *ACT1* was performed by using Power Sybr Green mix with ROX (Life Technologies), supplemented with primers DCK1qFw and DCK1qRv, MIP1qFw and MIP1qFw, or ACT1qFw and ACT1qRv, at a final concentration of 120 nM in the AB 7300 (Life Technologies) instrument at default settings: 50 °C 2 min, 95 °C 10 min, 41 cycles at 95 °C for 15 s and 60 °C for 1 min, and one cycle at 95 °C for 15 s and at 60 °C for 15 s. Statistical analysis was performed through an unpaired two-tailed *t*-test.

2.4. Measurement of *petite* frequency and Ery^R^ mutant frequency {#s0030}
------------------------------------------------------------------

*Petite* frequency was measured in DWM-5A *mip1* strains and in W1BCK1 *mip1* strains as previously reported ([@bb0025]), and on YLV3t3m3 as previously reported ([@bb0030]) in at least four independent clones for each strain. Statistical analysis was performed through a paired two-tailed *t*-test.

Ery^R^ mutant frequency was measured using the method of the median ([@bb0320]) as previously described ([@bb0025]), except for YLV3t3m3 *mip1* strains, which were not grown on SC medium but on YP medium supplemented with 2% galactose. Each value is the mean of three independent fluctuation test experiments with 16--20 samples each. Statistical analysis of Ery^R^ mutant frequency was performed through an unpaired two-tailed *t*-test.

2.5. Measurement of mtDNA levels {#s0035}
--------------------------------

W1BCK1 and YLV3t3m3 wild type and mutant strains were grown in the same condition used to determine *petite* frequency. Total DNA was extracted as previously reported ([@bb0130]). qPCR was performed on mtDNA gene *COX1* and, as reference, on nDNA gene *ACT1* using primers COX1-forward and COX1-reverse ([@bb0290]), and ACT1Fw and ACT1Rv as reported in [Section 2.3](#s0025){ref-type="sec"}.

3. Results {#s0040}
==========

3.1. Polymorphism selection and *in silico* analysis {#s0045}
----------------------------------------------------

A large number of polymorphisms have been found in the POLG(1) gene and their descriptions are collected in databases of the NHLBI exome sequencing project, in the SNP database from NCBI, and in the Human DNA Polymerase γ Mutation Database. We examined these databases to select suitable polymorphisms for our study, in particular those i) which have been found with a frequency higher than 0.1% and ii) which involve substitutions of an amino acid which is conserved between yeast and human or which is located in a region conserved between the two organisms. The latter is a prerequisite to be able to introduce the corresponding mutation in the ortholog position of the yeast Mip1 protein.

The NHLBI GO Exome Sequencing Project database (<http://evs.gs.washington.edu/EVS/>) contains data from the exome sequencing of more than 6200 people, of which approximately 2000 are African--American and 4300 are European--American unrelated individuals. Among the 283 POLG SNPs found in the database, 81 are coding and missense, of which 17 have a frequency higher than 0.1% in either the African--American (AA) population or in the European--American (EA) population (Supplementary Table 2).

The NCBI SNP database (<http://www.ncbi.nlm.nih.gov/snp>) contains 842 human SNPs in POLG, most of which derive from the 1000 Genomes Project. Four of these SNPs have been verified and have a MAF (Minimal Allele Frequency) higher than 0.001 or 0.1% (Supplementary Table 3).

The Human DNA Polymerase γ Mutation Database (<http://tools.niehs.nih.gov/Polg/>) describes approximately 250 mutations and polymorphisms obtained from literature. Of these mutations, 15 are reported as neutral polymorphisms with an allele frequency higher than 0.1% (Supplementary Table 4).

Among the 28 polymorphisms selected on the basis of their frequency, two were unambiguously reported to be pathological (T251L, A467T) (<http://tools.niehs.nih.gov/Polg/>) and for that reason they were excluded.

In order to analyze the level of conservation of the mutated residues, Pol γ protein sequences from different organisms were aligned in order to identify which of the polymorphisms involved residues conserved between humans and yeast. This analysis revealed that 18 mutations out of 26 involve amino acids which are not conserved or are located in a poorly conserved region. The remaining eight polymorphisms are variations of conserved (P241L, G268A, L392V, E1143G) or semi-conserved residues (R193Q, R964C, R1142W, R1146C), and are located in a conserved region (Supplementary Fig. 1).

P241L has been identified as a change present in 1 among 200 controls and as a polymorphism present in the Chinese population with an allelic frequency of 12--15% ([@bb0115; @bb0185]). G268A has been considered associated with sporadic progressive external ophthalmoplegia (PEO) in several studies. On the basis of further analysis, and considering its high frequency in the population (0.5--3.5%), this change is unlikely to be a pathological SNP or a phenotypic modifier ([@bb0285]; <http://jmg.bmj.com/content/48/10/669/reply#jmedgenet_el_989>). R964C was considered a pathological mutation, causing severe ataxia in heterozygosity with a second detrimental mutation ([@bb0260; @bb0285; @bb0305]). However, a patient homozygous for this mutation did not suffer from mitochondrial disorders, but developed lactic acidosis after a 1-year treatment with stavudine ([@bb0315]). It was also demonstrated that the *in vitro* polymerase activity of Pol γ harboring R964C is reduced 5 to 9-fold ([@bb0015; @bb0315]), with a 3-fold decreased ability to discriminate between dTTP and stavudine triphosphate (d4TTP) compared to that of the wt, thus explaining the stavudine sensitivity of the subject. The involvement of the mutation E1143G with a pathological phenotype has been described with contradictory conclusions. In addition, in heterozygosity E1143G has been statistically associated with a higher probability of developing liver failure after treatment with valproic acid ([@bb0255]) or stavudine-induced lipodystrophy ([@bb0070]). No information is available on the other polymorphisms taken into consideration.

At first, we performed an *in silico* prediction analysis of the phenotypic consequences of such polymorphisms, by using five different prediction tools. Although all the prediction algorithms are based principally on the conservation of the involved amino acid during the evolution and, for some programs, other parameters, the results obtained were not consistent (Supplementary Table 4). However, by performing a consensus of the results obtained *via* these five tools, two polymorphisms (R193Q and P241L) were predicted to be neutral, two polymorphisms (L392V and E1143G) possibly damaging and four polymorphisms (G268A, R964C, R1142W and R1146C) probably damaging (Supplementary Table 5).

3.2. Effect of the selected polymorphisms on mtDNA extended and point mutability {#s0080}
--------------------------------------------------------------------------------

The effect of the selected POLG polymorphisms on the mtDNA stability was evaluated *in vivo* in yeast strains carrying *MIP1* alleles containing mutations in the equivalent positions. In order to obtain these allelic variants, mutations which determine substitutions of conserved residues (P241L, G268A, L392V, E1143G) were inserted in wt *MIP1* cloned in the centromeric vector pFL39, by site-directed mutagenesis. In the case of mutations in non-conserved positions (R193Q, R964C, R1142W, R1146C), we constructed two alleles for each polymorphism: in the former, the Mip1 amino acid was changed according to the wt Pol γ (humanized allele); in the latter, the Mip1 amino acid was changed according to the polymorphism (mutant allele). All *mip1* alleles were introduced in the DWM-5A (*mip1*Δ) strain containing *MIP1* wt cloned in the pFL38 vector ([@bb0040]), thus obtaining a first series of strains containing both the mutant and the wt alleles (heteroallelic strains), which were used in the case of dominance/recessive tests. By plasmid shuffling on 5-FOA, we then obtained a second series of strains containing only the mutant *mip1* allelic variants (haploid strains).

We first evaluated the frequency of *petite* mutation in haploid strains, in order to determine whether polymorphisms behaved as neutral or if they altered the ability of DNA polymerase γ to fully replicate mtDNA. Analyses were performed at 28 °C, the optimal growth temperature for yeast, as well as at 37 °C, which is the temperature normally used to evaluate thermo-sensitivity of a given mutant in yeast.

Five out of eight polymorphisms (P241L, G268A, R964C, R1142W and E1143G) showed increased *petite* frequency at 28 °C, suggesting that they affect mitochondrial stability and thus are not neutral substitutions ([Fig. 1](#f0005){ref-type="fig"}). As mentioned above, three of them (G268A, R964C and E1143G) were already known to alter the properties of Pol γ. In addition, the five polymorphisms, together with R1146C, showed a strong thermosensitivity, suggesting that the mutation altered the stability and/or the catalytic properties of Pol γ at higher temperatures. As regards point mutability, most polymorphisms increased the frequency of Ery^R^ point mutations, ranging from a \~ 2-fold increase for R1146C and E1143G mutations to \~ 4-fold increase for P241L and G268A mutations ([Fig. 2](#f0010){ref-type="fig"}).

We then evaluated the dominance/recessivity of the phenotype. It has previously been demonstrated that a hemizygous diploid yeast strain *MIP1/mip1*Δ is haploinsufficient, *i.e.* it showed a \~ 2-fold increase in both extended and point mutability ([@bb0040]). Among the recessive mutants, it is thus possible to distinguish mutant alleles, which totally or partially complement the haploinsufficient phenotype of the *MIP1/mip1*Δ strain or which behave as a null allele. In the first case, the *petite* frequency and/or the Ery^R^ frequency are similar or slightly higher compared to those of the wt homozygous strain. In the second case, the *petite* frequency and/or the Ery^R^ frequency are similar to those of the hemizygous diploid strain. We found that all the polymorphisms are recessive concerning extended mutability and fully complement the *MIP1/mip1*Δ phenotype (data not shown). On the other hand, the two mutations in the exonuclease domains (P241L and G268A) are dominant in regard to the Ery^R^ mutant frequency, which was 2.3 to 3.2-fold higher, respectively, compared to that of the heterozygous diploid strain.

3.3. Effect of the selected polymorphisms in combination with a pathological mutation {#s0055}
-------------------------------------------------------------------------------------

Several pathological mutations in POLG have been found *in cis* with one or more polymorphisms. However, in most cases, it is not clear whether the pathology and the severity of the disease are caused only by the pathological mutation(s), or if the polymorphism could behave as a phenotypic modifier which improves or worsens the pathological phenotype. We have previously demonstrated in yeast that mutation equivalent to E1143G polymorphism increased the *petite* frequency of the A889T-equivalent mutation in *MIP1* when *in cis*, since the presence of the former mutation decreased soluble protein levels of Mip1 ([@bb0020]). In order to determine whether other polymorphisms have the capability to increase the mtDNA instability when *in cis* with a pathological mutation, we analyzed the effect of the selected polymorphisms in combination with the A889T-equivalent mutation A692T. We showed that all the polymorphisms except for R193Q behaved as phenotypic modifiers that increased the *petite* frequency of the mutant Mip1^A692T^ ([Fig. 3](#f0015){ref-type="fig"}). For most polymorphisms, including E1143G, the effects were additive, *i.e.* the polymorphism increased the *petite* frequency by the same degree as in the presence of wt Mip1. Furthermore, two polymorphisms, L392V and R1146C, which were found to be neutral in the absence of other mutations at 28 °C, caused a 1.6 and a 2.1-fold increase in the *petite* frequency in the presence of the A889T mutation.

3.4. Analysis of the toxicity induced by NRTI treatment in the presence of the selected polymorphisms: effect of stavudine {#s0060}
--------------------------------------------------------------------------------------------------------------------------

We then analyzed if the presence of mutations in DNA polymerase γ correlated with a variation of mitochondrial toxicity due to NRTI treatment, in particular stavudine or zalcitabine.

d4T is active as an inhibitor of Pol γ (and of HIV reverse transcriptase) after import into the cell and triphosphorylation by thymidine kinase and thymidylate kinase. *S. cerevisiae* is not able to mediate deoxynucleosides uptake and lacks the enzyme required to catalyze the first phosphorylation, and therefore it is unable to activate nucleosides from the environment, as well as to activate NRTI. For our experiments, we took advantage of a yeast strain expressing the human *ENT1* (*hENT1*) gene, encoding the equilibrative nucleoside transporter, and the thymidine kinase gene from the herpes simplex virus (*HSV-TK*), which was integrated in the yeast genome under the control of *GAL1-10* promoter (strain YLV3) ([@bb0300]). The observation that the mtDNA mutability increased in the YLV3 strain after treatment with d4T in galactose, but not in glucose, demonstrated that the expression of *hENT1* and *HSV-TK* mediated the uptake and the activation of d4T and the consequent mitochondrial toxicity due to incorporation of the NRTI in the *S. cerevisiae* mtDNA by Mip1. This model system has been validated by assessing the association between d4T toxicity and expression of *mip1* alleles carrying mutations known to be sensitive to stavudine in human patients ([@bb0035]). Moreover, by Northern analysis and RT-qPCR, we showed that the mRNA levels of *hENT1*, *HSV-TK* and *MIP1* were influenced neither by the levels of d4T added to the medium nor by the concentration of galactose ranging from 0.3% to 2% (Supplementary Fig. 2). From YLV3 we obtained a series of strains deleted of the *MIP1* gene (YLV3t3m3) and harboring *mip1* alleles carrying the different selected polymorphisms, cloned in the centromeric vector pFL39. The mtDNA toxicity was studied in these strains after treatment with 1 mM d4T, by measuring the frequency of *petite* mutants. The frequency of *petite* mutants was increased by d4T treatment in YLV3t3m3 carrying both wt and mutant *mip1* alleles (Supplementary Table 6). The Mip1 variant corresponding to human polymorphisms G268A, L392V, R964C and E1143G rendered the strain more susceptible to d4T than wt Mip1, since the ratio of *petite* frequency between treated and untreated mutant strain normalized to the wt strain was higher than 1 ([Fig. 4](#f0020){ref-type="fig"}A). In particular, data related to R964C and E1143G were in agreement with what has been observed in humans ([@bb0015; @bb0315]). On the contrary, variant P241L renders Mip1 less susceptible to the NRTI (ratio of *petite* frequency between treated and untreated mutant strains normalized to wt strain lower than 1). In the case of polymorphisms R193Q, R1142W and R1146C, the effect of stavudine and the effect of the polymorphism were additive (the ratio of *petite* frequency between treated and untreated mutant strains normalized to wt strain is not significantly different from 1).

We further measured through qPCR the mtDNA levels after treatment with d4T. We observed that in the YLV3t3m3 *MIP1* strain the mtDNA copy number decreased approximately of 2.2-fold compared to the untreated condition. Since treatment with the same concentration of d4T resulted in a *petite* frequency, *i.e.* respiratory deficient cells without an intact mtDNA, of approximately 20% (Supplementary Table 6), the qPCR results clearly show that d4T treatment reduces the level of mtDNA to 50% in respiratory competent cells. Treatment with d4T in *mip1* mutant strains with increased *petite* frequency results in decreased mtDNA levels compared to the treated wild type strain, indicating that, in presence of *mip1* polymorphisms, d4T not only increased the number of respiratory deficient cells but also decreased the mtDNA levels in the whole cell population ([Fig. 4](#f0020){ref-type="fig"}B).

Due to the low frequency of Pol γ polymorphisms in the human population, the majority of subjects carrying these polymorphisms are heterozygous. To mimic this condition, we constructed YLV3t3m3 heteroallelic strains bearing a copy of both wt *MIP1* and of one of each mutant allele, as well as a homoallelic strain bearing two copies of wt *MIP1*. *Petite* frequency was measured after treatment with 2 mM d4T, the optimal concentration to assess the dominant/recessive behavior of mutant alleles in the presence of stavudine ([@bb0035]). Heteroallelic strains carrying Mip1 variants corresponding to G268A, L392V, R964C and E1143G Pol γ polymorphisms displayed a significant increase of mitochondrial mutability, compared to the homoallelic strain, indicating that these mutations behave as dominant concerning d4T toxicity ([Fig. 4](#f0020){ref-type="fig"}C and Supplementary Table 7). As for haploid strains, treatment with 2 mM d4T results in decreased mtDNA copy number for G268A, L392V, R964C and E1143G Pol γ polymorphisms in heterozygosis ([Fig. 4](#f0020){ref-type="fig"}D).

The effect of stavudine on point mutations was also analyzed in haploid strains carrying mutant alleles. After treatment with 1 mM d4T, the Ery^R^ mutant frequency increased in all strains, including those harboring wt *MIP1* (Supplementary Table 8, columns 2 and 3). In addition, the fold increase, expressed as ratio between treated mutant strain and treated wt, is greater than 1 for most mutant strains, indicating that the simultaneous presence of a *MIP1* mutator allele in and of d4T is detrimental for the fidelity of mtDNA replication ([Fig. 5](#f0025){ref-type="fig"}A). However, if the fold increase is further normalized with the untreated wt strain, the effect between the intrinsic mutability of mutant Mip1 and the susceptibility to d4T are synergistic only in the case of mutations R964C and E1143G (normalized fold increase higher than 1), whereas mutation P241L is less susceptible to the presence of d4T (normalized fold increase lower than 1) ([Fig. 5](#f0025){ref-type="fig"}B), as already observed in the case of extended mutability.

3.5. Analysis of the toxicity induced by NRTI treatment in the presence of the selected polymorphisms: effect of zalcitabine {#s0065}
----------------------------------------------------------------------------------------------------------------------------

Zalcitabine (ddC), similarly to stavudine, is active after phosphorylation in the cell. Strains derived from YLV3t3m3 were found insensitive to the toxicity induced by this NRTI (data not shown), probably either because *hENT1* is unable to transport zalcitabine, or because *HSV-TK*, which is reported to phosphorylate other deoxypyrimidines ([@bb0065]), is unable to phosphorylate it, or both. In order to improve the import of ddC, *hENT1* was deleted in the YLV3t3m3 strain and substituted with human *CNT3* cDNA. *hCNT3*, together with h*CNT1* and h*CNT2*, belongs to the *SCL28* family of Na-coupled concentrative nucleoside transporters, responsible for the high affinity transport of both nucleosides and synthetic nucleoside analogs in mammals ([@bb0110]). *hCNT3* was chosen since it was characterized as broadly selective for both purine and pyrimidine nucleosides. *hCNT3* is also able to transport a number of anticancer and antiviral nucleoside analogs, including ddC ([@bb0110]). *hCNT3* cDNA was cloned under the control of the *GAL1-10* promoter both in the centromeric pUSG-E12 and in the multicopy pYES2 vectors. These recombinant plasmids were then introduced into YLV3t3m3 devoid of *hENT1*, and the correct expression and galactose induction of *hCNT3* were verified by Northern blot (data not shown). Strains expressing *hCNT3*, both in monocopy and in multicopy, treated with ddC, did not exhibit mitochondrial toxicity (data not shown), suggesting that, in this case also, the nucleoside analog was not correctly transported and/or phosphorylated to the metabolically active form.

A new strain was then constructed by genomic integration of the human deoxycytidine kinase cDNA (*DCK1*), under the control of a constitutive *PGK* promoter, thus obtaining the W1BCK1 strain. To test the ddC sensitivity of this recombinant strain, we treated it with increasing concentrations of ddC. Mitochondrial toxicity was then analyzed by measuring the frequency of *petite* mutants. As reported in [Fig. 6](#f0030){ref-type="fig"}, the frequency of *petite* mutants increased in a dose dependent manner, indicating that: i) ddC was transported into the yeast cell, probably by aspecific transporters; ii) ddC was phosphorylated and activated to the metabolic active form by *hDCK1* in yeast. Moreover, we demonstrated by RT-qPCR that the *MIP1* and hDCK1 mRNA levels were not influenced by the presence and the concentration of ddC (Supplementary Fig. 3).

From W1BCK1 we obtained a series of strains deleted of the *MIP1* gene (W1BCK1-10) and harboring *mip1* alleles carrying the different selected polymorphisms, cloned in the centromeric vector pFL39.

In order to validate the system, we took advantage of biochemical data previously obtained on human Pol γ mutants. It has been reported that human Pol γ harboring E895A or Y951F mutations showed an \~ 18-fold and 2400-fold decrease respectively, in incorporation of ddCTP relative to dCTP compared to wt Pol γ, indicating a lower susceptibility to ddC toxicity ([@bb0180]). Thus, we tested whether we could observe a similar effect in the W1BCK1-10 yeast strain carrying mutations E698G and Y753F in the equivalent positions. In the haploid strain these mutations induce 100% *petite*; in the heteroallelic strain, both mutant *mip1* alleles behaved as negative dominant, increasing the *petite* frequency compared to a strain harboring a copy of wt *MIP1*, *i.e.* the hemiallelic strain (11.6% and 18.7% respectively, vs 2.0%). This effect is coherent with the dominant pathological phenotype observed in patients heterozygous for mutations in the same position ([@bb0250; @bb0285]). We found that, following treatment with ddC, the *petite* frequency of both heteroallelic and hemiallelic strains increased (data not shown) in the case of both mutations E895G and Y951F, but the ratios of *petite* frequency of the heteroallelic strain to *petite* frequency of the hemialleic strain decreased significantly by increasing ddC concentration ([Fig. 7](#f0035){ref-type="fig"}). This result indicated that, when E895G and Y951F mutant isoforms are present, Mip1 is less susceptible to ddC toxicity, thus parallelizing with the biochemical results previously obtained in Pol γ.

Once we had validated the model, we tested extended and point mutability in W1BCK1-10 harboring the *mip1* alleles that carry the different selected polymorphisms. Regarding *petite* frequency in haploid strains ([Fig. 8](#f0040){ref-type="fig"}A and Supplementary Table 9), only the Mip1 variants corresponding to human polymorphisms G268A and R964C were more susceptible to ddC than wt Mip1. Mip1 mutants harboring substitutions L392V and E1143G, which were sensitive to d4T, were not sensitive to ddC compared to the wt, as well as R193Q, R1142W and R1146C variants. As observed for d4T, treatment with ddC results in a 3.2-fold decrease of mtDNA levels in *MIP1* wild type strain, indicating that respiratory competent cells retain approximately 30% of the mtDNA levels. Again, strains with increased *petite* frequency (Supplementary Table 9) display also a reduced mtDNA copy number after treatment with ddC ([Fig. 8](#f0040){ref-type="fig"}B). Among the heteroallelic strains, only the strain harboring R964C showed a dominant effect in the presence of ddC ([Fig. 8](#f0040){ref-type="fig"}C and D and Supplementary Table 10).

All strains showed an increase of Ery^R^ mutant frequency after treatment with ddC (Supplementary Table 11, columns 2 and 3). The fold increase was significantly greater than 1 only for three mutations ([Fig. 9](#f0045){ref-type="fig"}A). The fold increase normalized with the untreated wt strain showed a synergistic effect of the intrinsic mutability of mutant Mip1 and of the susceptibility to ddC only for the G268A mutation ([Fig. 9](#f0045){ref-type="fig"}B). On the contrary, the P241L mutation was less susceptible to the presence of ddC, as already observed in the case of d4T.

4. Discussion {#s0070}
=============

Mutations in amino acid residues which have a relatively high frequency in the population are generally considered neutral. However, several amino acid substitutions, despite not being the cause of pathology, may modulate the effect of pathological mutations or alter the effect of a drug. In recent years, the use of next generation sequencing has strongly increased the number of sequenced genomes or exomes, revealing the existence of a high number of mutations in the population, or in specific ethnic groups, most of which have a low frequency and are not characterized.

Pol γ, the mitochondrial replicase, is among the most studied mitochondrial proteins and its activity is fundamental for the maintenance of adequate levels of mtDNA. Physiological, biochemical and phenotypic consequences of pathological mutations have been described, whereas little is reported concerning amino acid substitutions which have low frequency and are considered neutral. Firstly, if the biochemical effect of a mutation is small, kinetic studies may not point out the defects caused by this mutation, such as changes in the K~m~, in the k~cat~ or in the processivity of Pol γ. Secondly, if the mutation frequency is low, it could be difficult to find a statistical correlation between the presence of the mutation and a pathological phenotype or an altered response to a drug in the population. Thus, the use of an *in vivo* system with high sensitivity, such as the model organism *S. cerevisiae* which we are proposing, can sharpen the putative defects caused by mutations/polymorphisms, in particular on extended mitochondrial mutability or on point mutability. We introduced eight polymorphisms in the yeast *MIP1* gene, which was chosen on the basis of the frequency in the population and of the conservation between yeast and human Pol γ. Quite surprisingly, six among them (75%) increased the *petite* frequency or the Ery^R^ frequency. The observed variations were modest, indicating that the polymorphisms should not be pathological alone, but suggesting that their presence can contribute to increasing the levels of mutant mtDNA in the cell. The two mutations in the exonuclease (exo) domain, P241L and G268A, increased the point mutability at higher levels, suggesting that mutant Pol γ harboring these mutations, as well as other exo domain mutations lying in the protein surface ([@bb0090]), have a reduced ability to remove mismatched nucleotides. In addition, G268A is predicted to lie in a cluster, which comprises residues 268--277, for which a decrease in exonuclease activity is predicted if mutated ([@bb0095]). Six mutations also determine a strong thermosensitivity. Among them is the E1143G mutation, which has been reported to have a decreased *in vitro* activity at high temperatures ([@bb0060]). Interestingly, R1142, E1143 and R1146 are located in a β-sheet that surrounds the catalytic site in the palm subdomain and can therefore maintain the architecture of the active site ([@bb0090]), suggesting that mutations in these amino acids can alter the tertiary structure, especially at high temperatures.

In many patients, several pathological mutations have been identified together with one or more polymorphisms considered as neutral. This suggests that, at least in some cases, a neutral polymorphism can modify the phenotype associated with a pathological mutation. Little information is known in this regard, with the exception of the E1143G mutation. Biochemical studies on human Pol γ harboring this mutation have been contradictory. [@bb0060] found that mutant E1143G Pol γ has a 1.4-fold higher catalytic activity than wt Pol γ, and that this mutation can partially rescue the strong biochemical defects of the W748S mutation *in cis*. On the contrary, [@bb0200], showed that human Pol γ harboring the W748S mutation does not show any biochemical defects and behaves like wt Pol γ *in vivo*, and that the presence *in cis* of the E1143G mutation does not alter the *in vivo* behavior of the mutant protein. We previously showed that the presence of the E1143G-equivalent mutation in yeast decreases the mtDNA stability by 2-fold because of the A889T mutation, due to the reduced stability of the protein harboring both mutations compared to a protein harboring only the latter mutation ([@bb0020]). Therefore, this mutation, identified at the beginning as a neutral polymorphism, is now considered a phenotypic modulator of pathological mutations *in cis*.

In order to evaluate the possible role of the selected polymorphisms as phenotypic modifiers, we measured the *petite* frequency in strains harboring the A889T-equivalent mutation *in cis* with the polymorphism under analysis. This mutation was chosen as a reference since, to our knowledge, this is the only pathological mutation, besides the non-conserved substitution W748S, that has been shown *in vivo* to have a worse phenotype when *in cis* with a polymorphism ([@bb0020]). We showed that all the polymorphisms, except for E193Q, had negative effect, indicating that they could potentially modulate the pathological phenotype. For two polymorphisms, L392V and R1146C, the effect in combination with the A889T mutation was synergistic.

A limitation to the use of yeast *MIP1* to study the effects of mutations is that only conserved or semi-conserved residues can be studied. During the preparation of this manuscript, Qian and co-authors created a yeast model system in which both human Pol γ subunit genes, cloned under the yeast *MIP1* promoter and in frame with the *MIP1* fragment encoding the mitochondrial targeting signal, complement the absence of *MIP1*, indicating that human Pol γ can replicate yeast mtDNA ([@bb0215]). Interestingly, a comparison between the effects of four human mutations which have been studied both in the human POLG and in the *MIP1* gene showed very similar results concerning mtDNA stability, mtDNA point mutability and dominance/recessivity in the two systems, indicating that the use of yeast *MIP1* has a good predictive ability for conserved and semi-conserved residues. However, the creation of a yeast strain expressing human POLG will be an unequaled model for the *in vivo* studies of non-conserved mutations.

An additional point addressed in this work concerns the role of the yeast model in predicting the possible correlation between specific mutations in Mip1, corresponding to human mutations, and mtDNA mutability induced by treatment with nucleoside reverse transcriptase inhibitors (NRTI), used in the highly active antiretroviral therapy (HAART), *i.e.* d4T and ddC. These molecules are inhibitors of Pol γ, at least in their triphosphorylated forms, as observed in different studies ([@bb0135; @bb0175; @bb0190]). We showed that, as for HIV reverse transcriptase and human Pol γ, yeast Mip1 is inhibited more by ddC than d4T, because 30 μM of ddC are enough to increase the *petite* frequency to 20% compared to 1 mM of d4T. Based on the "Pol γ hypothesis" of NRTI toxicity, each mutation/SNP which changes the Pol γ affinity for the incoming NRTI-TP, the discrimination between the NRTI-TP and the corresponding dNTP, or the NRTI excision efficiency in the mtDNA could alter the NRTI induced toxicity. To date, an association between NRTI-induced mitochondrial toxicity and SNPs/mutations in Pol γ has been reported for two mutations, R964C and E1143G ([@bb0070; @bb0315]).

Our previous and present results showed that mutant versions of Mip1 harboring four polymorphisms (G268A, L392V, R964C and E1143G) are more sensitive to d4T-induced mitochondrial toxicity, resulting in higher *petite* frequency and Ery^R^ mutant frequency, and lower mtDNA levels, than those observed in Mip1 wt strain treated with d4T. In addition, for all these polymorphisms, the effects of stavudine toxicity on mtDNA stability are dominant, *i.e.* a heteroallelic strain harboring a wt copy of Mip1 and a mutant copy of Mip1 showed higher *petite* frequency in the presence of d4T as well as a decrease in total mtDNA levels compared to a strain harboring two copies of wt Mip1. This result indicates that also heterozygous subjects, who are more frequent than homozygous ones due to the relative low frequency of these polymorphisms, are susceptible to d4T toxicity, as already observed in patients heterozygous for E1143G or R964C.

Interestingly, Mip1 harboring a P241L mutation is less susceptible to d4T-induced extended and point mutability, suggesting that mutant polymerase either binds with a lower affinity d4T-TP or has an increased ability to remove incorporated d4T. Additionally, P241L is part of a cluster which also includes residues 224--244 and which is predicted to decrease polymerase activity and to increase exonuclease activity if mutated ([@bb0095]).

Regarding ddC, we observed that only two polymorphisms, G268A and R964C, determined an increased sensitivity to the NRTI, and only for the latter the effects are dominant. This suggests that this NRTI could be better tolerated compared to d4T in HIV patients harboring polymorphisms. Again, P241L is less sensitive to ddC toxicity.

We have previously demonstrated that extended mtDNA mutability (*petite* frequency) and Ery^R^ point mutability due to mutations in Mip1 are derived from different mechanisms, since for most mutations there is no correlation between increase in the former and increase in the latter. It is worth noticing that, for both the NRTIs analyzed, we showed in this study that there was a significant correlation between induced extended mutability (*petite* frequency) and induced point mutability (Ery^R^ mutant frequency), suggesting, but not demonstrating, a cause/effect relationship. Although this observation cannot exclude that the NRTI caused, as a direct effect, both an increase in *petite* frequency and in point mutability, the results are coherent with those of [@bb0205], who demonstrated that mtDNA mutations accumulated in cells from patients treated with NRTIs are not due to *de novo* point mutations induced by the NRTI, but might instead be caused by the clonal expansion of preexisting mutant mtDNA particles, needed to restore a proper mtDNA level in case of mtDNA depletion consequent to the NRTI treatment.

5. Conclusions {#s0075}
==============

In this work we studied the effects of eight polymorphisms in the DNA polymerase γ gene, which are one third of the known human polymorphisms with a frequency higher than 0.1%, on the mtDNA stability and point mutability in an *in vivo* system. This study suggests that many human SNPs/mutations in POLG (i) are not neutral, (ii) could potentially behave as phenotypic modulators of pathological mutations and (iii) can increase the mitochondrial dysfunction induced by treatment with NRTIs. The analysis is based on the general assumption that if an amino acid is conserved between two homologous proteins, such as Mip1 and human Pol γ, the substitution of that amino acid in one protein can predict the effect of the mutation in the second protein. However, it must be underlined that this assumption is not applicable for any proteins/amino acids, especially if the amino acid lies far from the active site. In the case of Pol γ, the sequence identity between human and yeast enzymes is approximately 45%, with peaks of 65--70% in the exonuclease and polymerase domains, and lows in the linker domain, which in yeast is shorter, lacking the POLG2 subunit binding subdomain. For these reasons, our results should be confirmed by studies of the polymorphisms in mammalian Pol γ, either in the yeast model system expressing human Pol γ or in mammalian cells or in a mammalian model system, especially in the case of substitutions of amino acids which contribute to the binding of the POLG2 subunit, absent in yeast.

From a pharmacogenetic point of view, we found that, in the presence of polymorphisms in POLG, zalcitabine should be better tolerated than stavudine since a lower number of polymorphisms determined ddC-induced toxicity and the detrimental effects are less significant in the case of ddC. These results agree, in general, with clinical observations, which showed that d4T is commonly less tolerated than ddC, and in particular with the observation that there is a correlation between the presence of E1143G polymorphism and induced lipodystrophy in the case of d4T treatment, but not of ddC treatment ([@bb0070]). Hence, our analysis supports the need of developing novel NRTIs which inhibit HIV reverse transcriptase but not Pol γ, and stresses the importance of monitoring the effects of such NRTIs by biochemical and/or *in vivo* analysis on wt and mutant DNA polymerase γ. Such an approach has been recently applied for the novel NRTIs 3′-fluoro-3′-deoxythymidine (FLT) and 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine (Ed4T) ([@bb0235]), which showed that the former, once triphosphorylated, showed only a 35-fold discrimination compared to dTTP, whereas Ed4T-tryphospate showed a 6200-fold discrimination. However, DNA polymerase γ harboring R964C may lead to a higher degree of mitochondrial toxicity in the presence of Ed4T-tryphospate, as observed previously *in vivo* ([@bb0315]), *in vitro* ([@bb0015]) and in this study for d4T. Therefore, it is necessary to consider the presence of SNPs that can lead to unexpected side effects when developing new NRTIs.

Appendix A. Supplementary data {#s0085}
==============================

Supplementary Fig. 1. Alignment of DNA polymerase γ protein sequences from different organisms. Hs: *Homo sapiens*, Pt: *Pan troglodytes*, Mm: *Mus musculus*, Xl: *Xenopus laevis*, Dr: *Danio rerio*, Sc: *Saccharomyces cerevisiae*.Supplementary Fig. 2. (A) Northern blot on *hENT1* and *HSV-TK* mRNA. For each gene, strain and condition, the signal was normalized for the signal of *ACT1* mRNA. An arbitrary value of 1 has been assigned to the YLV3 strain grown on 2% galactose. The values are mean of two independent experiments. (B) RT-qPCR on *MIP1* mRNA. An arbitrary value of 1 has been assigned to the YLV3 strain grown on 2% galactose. The values are mean of three independent experiments ± standard deviation.Supplementary Fig. 3. RT-qPCR on *MIP1* and *hENT1* mRNAs. An arbitrary value of 1 has been assigned to the W1BCK1 strain in the absence of ddC. The values are mean of three independent experiments ± standard deviation.Supplementary tables.
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![*Petite* mutant frequency in *mip1* wt and mutant strains at 28 °C (left panel) and 37 °C (right panel). In brackets the corresponding substitution in yeast Mip1. The letter "h" before the substitution indicates the humanized wt allele of the corresponding human substitution. The values are mean of three independent experiments ± standard deviation. Statistical significance: \*: p \< 0.05; \*\*: p \< 0.01; \*\*\*: p \< 0.001.](gr1){#f0005}

![Ery^R^ mutant frequency in *mip1* wt and mutant strains. The frequency of Ery^R^ mutants was calculated as the ratio of the number of Ery^R^ mutants to the number of *rho^+^* cells plated on the Petri dish. The 'fold increase' was calculated by normalization of the wt *MIP1* strain relative frequency, which was 2.3 × 10^− 7^, to 1. Legend and statistical significance are as in [Fig. 1](#f0005){ref-type="fig"}.](gr2){#f0010}

![*Petite* frequency in *mip1* mutants in combination with the human A889T (yeast A692T) mutation. Legend and statistical significance are as in [Fig. 1](#f0005){ref-type="fig"}.](gr3){#f0015}

![(A) Normalized *petite* fold increase of strains treated with 1 mM d4T relative to untreated strains. For each mutant, the normalized *petite* fold increase is the mean of the ratios \[(*petite* frequency of treated mutant strain)/(*petite* frequency of untreated mutant strain)\]/\[(*petite* frequency of treated wt strain)/(*petite* frequency of untreated wt strain)\] (see also Supplementary Table 6). For mutant strains harboring human substitutions P193Q, R964C, R1142W and R1146C, the frequencies were compared to strains harboring the corresponding *mip1* humanized allele. (B) mtDNA levels in strains with a higher normalized *petite* fold increase after treatment with 1 mM d4T. The ratio *COX1*/*ACT1* was normalized to 1 for wild type strain. (C) Normalized *petite* fold increase of heteroallelic strains treated with 2 mM d4T compared to homoallelic strain treated with 2 mM d4T. For each mutant, the normalized *petite* fold increase is the ratio (*petite* frequency of treated mutant strain/*petite* frequency of treated wt strain) (See also Supplementary Table 7). For mutant *MIP1*/*mip1* strains harboring human substitutions R964C, R1142W and R1146C, the frequencies were compared to strains harboring the corresponding *MIP1/mip1* humanized allele. Statistical significance is as in [Fig. 1](#f0005){ref-type="fig"}. (D) mtDNA levels in heteroallelic strains with a higher *petite* fold increase after treatment with 2 mM d4T. The ratio *COX1*/*ACT1* was normalized to 1 for homoallelic wild type strain.](gr4){#f0020}

![(A) Ery^R^ fold increase of mutant strains treated with 1 mM d4T relative to treated wt strain. For each mutant, the fold increase (treated mutant/treated wt) is the mean of the ratios (Ery^R^ frequency of treated mutant strain/Ery^R^ frequency of treated wt strain). (B) Ery^R^ normalized fold increase of mutant strains treated with 1 mM d4T compared to untreated strains. For each mutant, the normalized fold increase (treated/untreated) is the mean of the ratios \[(Ery^R^ frequency of treated mutant strain)/(Ery^R^ frequency of untreated mutant strain)\]/\[(Ery^R^ frequency of treated wt strain)/(Ery^R^ frequency of untreated wt strain)\] (See also Supplementary Table 8). For mutant strains harboring human substitutions P193Q, R964C and R1142W, the frequencies were compared to strains harboring the corresponding *mip1* humanized allele. Statistical significance is as in [Fig. 1](#f0005){ref-type="fig"}.](gr5){#f0025}

![Susceptibility to ddC of W1BCK1 strain treated with ddC from 0 (*petite* frequency equal to 1.2%) to 100 μM (*petite* frequency equal to 99.8%).](gr6){#f0030}

![Susceptibility to ddC of W1BCK1-10 *mip1* heteroallelic mutant strains compared to hemiallelic strain. In order to normalize the data to the zero value, at each concentration tested, the ratio of *petite* frequency of the heteroallelic strain to *petite* frequency of hemiallelic strain was calculated as \[(*petite* frequency of treated heteroallelic strain) -- (*petite* frequency of untreated heteroallelic strain)\]/\[(*petite* frequency of treated hemiallelic strain) -- (*petite* frequency of untreated hemiallelic strain)\]. Cells were treated with ddC ranging from 4 to 20 μM, and results were included if *petite* frequency of heteroallelic strain was lower than the threshold value of 50%. A linear regression curve was plotted by using the Excel linear regression function. Statistical analysis was performed using the ANOVA test of linearity. Significance was calculated by using the F distribution with one degree of freedom at the numerator and three or two degrees of freedom at the denominator.](gr7){#f0035}

![Legends and statistical analysis are as in [Fig. 4](#f0020){ref-type="fig"} except that 30 μM ddC and 60 μM ddC were used in (A) and (B), and in (C) and (D) respectively (see also Supplementary Tables 9 and 10).](gr8){#f0040}

![Legends and statistical analysis are as in [Fig. 5](#f0025){ref-type="fig"} except that 20 μM ddC was used (see also Supplementary Table 11).](gr9){#f0045}

###### 

Strains used in this work.

  Strain       Genotype                                                                                                          Origin
  ------------ ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------
  DWM-5A       *Matα ade2-1 leu2-3,112 ura3-1 trp1-1 his3-11,15 can1-100 mip1::Kan^R^*                                           [@bb0040]
  YLV3t3m3     *Mat**a** ade2-1 leu2-3,112::hENT1-LEU2 ura3-1 trp1-1::HSV-TK-trp1::Kan^R^ his3-11,15 can1-100 mip1::Hph^R^*      [@bb0035]
  W303-1B      *Matα ade2-1 leu2-3,112 ura3-1 trp1-1 his3-11,15 can1-100*                                                        [@bb9000]
  YLV3t3m3ΔH   *Mat**a** ade2-1 leu2-3,112::hENT1::SpHIS5 ura3-1 trp1-1::HSV-TK-trp1::Kan^R^ his3-11,15 can1-100 mip1::Hph^R^*   This study, disruption of *hENT1* with *SpHIS5* in YLV3t3m3
  W1BCK1       *Matα ade2-1 leu2-3,112::hDCK1-LEU2 ura3-1 trp1-1 his3-11,15 can1-100*                                            This study, integration of human *DCK1* at the *leu2 locus* of W303-1B
  W1BCK1-10    *Matα ade2-1 leu2-3,112::hDCK1-LEU2 ura3-1 trp1-1 his3-11,15 can1-100 mip1::Hph^R^*                               This study, disruption of *MIP1* with HphMX4 cassette in W1BCK1
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